A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Metastatic Carcinoma of the Pancreas
Latest Information Update: 20 Feb 2024
At a glance
- Drugs Exatecan (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 15 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 May 2012 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.
- 23 Jul 2008 Planned patient number is now 37 as reported by ClinicalTrials.gov.